Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...

Synthetic gene delivery vectors offer potential advantages over viral vectors for systemic administration. Ease of vector production, customization through conjugation of additional enhancement ...

Engineering retroviruses into vectors of therapeutic value has been a highly pursued effort. To date, the promise of retroviral-mediated gene delivery to treat or even cure genetic diseases has been ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...